Comparison of cardioprotective effects of salvianolic acid B and benazepril on large myocardial infarction in rats.
In the present study, we compared cardioprotective effects of salvianolic acid B (Sal B) and the angiotension-converting enzyme inhibitor, benazepril, in rats with large myocardial infarction (MI). The large MI was produced by coronary artery ligation for 4 weeks in rats. The rats were divided into the following groups: sham operation; MI; MI + Sal B (100 mg/kg by a gavage, once a day for 4 weeks) and MI + benazepril (1 mg/kg by a gavage, once a day for 4 weeks). Echocardiogram, hemodynamic and hemorheological changes, angiogenesis, infarct size and cardiac remodeling, as well as messenger ribonucleic acid (mRNA) of vascular endothelium growth factor (VEGF) were measured. The following similar effects were observed in MI rats treated with Sal B and benazepril: (1) a marked improvement of echocardiographic, hemodynamic and hemorheological parameters, (2) significant reduction of infarct size, (3) significantly attenuated heart hypertrophy, left ventricular (LV) dilatation and fibrosis. The unique effects of Sal B were: angiogenesis and augmented VEGF expression in the border and remote noninfarcted LV area. These results suggest that Sal B and benazepril exerted beneficial cardioprotective effects. However, Sal B enforced some different modality than benazepril, which might improve myocardial microcirculation by augmenting VEGF expression and promoting angiogenesis besides similar effects to benazepril.
He
Hai-Bo
HB
Institute of Chinese Herbal Medicine, College of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, China.
Yang
Xian-Zhe
XZ
Shi
Meng-Qiong
MQ
Zeng
Xiao-Wei
XW
Wu
Li-Mao
LM
Li
Lian-Da
LD
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D001572:Benzofurans / Q000494:pharmacology / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003094:Collagen / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use; D004452:Echocardiography / Q000379:methods; D006439:Hemodynamics / Q000187:drug effects; D007150:Immunohistochemistry; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000187:drug effects; D008517:Phytotherapy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013318:Stroke Volume / Q000187:drug effects; D042442:Vascular Endothelial Growth Factors / Q000235:genetics / Q000378:metabolism; D016277:Ventricular Function, Left / Q000187:drug effects; D053630:Depsides
D000959:Antihypertensive Agents; D001552:Benzazepines; D001572:Benzofurans; D002316:Cardiotonic Agents; D003094:Collagen; D004365:Drugs, Chinese Herbal; D012333:RNA, Messenger; D042442:Vascular Endothelial Growth Factors; C076944:salvianolic acid B; D053630:Depsides; C044946:benazepril